• HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally.
• HBM1020 was generated from Harbour Mice^® H2L2 transgenic mice platform.
• HBM1020 has great potential to address huge unmet medical needs in patients with advanced malignancies.

HBM1020, generated from Harbour Mice^® H2L2 transgenic mice platform, is the first therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally.

"We are delighted to announce the dosing of the first patient with our first-in-class B7H7/HHLA2 antibody HBM1020," said Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed. "This milestone is a significant accomplishment for our team and represents a major step forward in our mission to transform patient care. We are excited about the potential of the B7H7/HHLA2 antibody to make a meaningful difference in the lives of patients suffering from advanced malignancies and we remain dedicated to advancing its clinical development globally."